Hyperuricemia is associated with atrial fibrillation prevalence in very elderly - a community based study in Chengdu, China

Gang Huang1,2, Rong-hua Xu1, Jun-bo Xu1,2, Ya liu1, Zhao-hui Liu1, Xue Xie1 & Ting-jie Zhang1

Hyperuricemia is a risk factor for cardiovascular diseases. However, in very elderly, the relationship between hyperuricemia and the prevalence of atrial fibrillation (AF) is not clear. This study aimed to investigate hyperuricemia and the risk of AF in community very elderly. In this cross-sectional study, 1056 very elderly in community were enrolled. Serum uric acid (SUA) were measured and rest 12-lead electrocardiogram was performed. Multiple logistic regression models were used to explore risk factors for AF in very elderly. Finally, 1038 participants were included in analysis and the mean age of the study participants were 83.6 ± 3.4 years (age range 80–100 years). The mean SUA level was 350.1 ± 84.5 μmol/L. The estimated prevalence of AF was 5.3%, and there was no significant sex difference (5.8% for men and 4.8% for women, p = 0.401). Multiple logistic regression found that participants with hyperuricemia (SUA > 416 μmol/L in men and > 357 μmol/L in women) had a higher risk (odds ratio: 2.080, 95% confidence interval: 1.103–4.202, P = 0.007) of suffering AF in very elderly Chinese. In conclusion, AF is relatively frequent in this community very elderly Chinese in Chengdu. Hyperuricemia is associated with the prevalence of AF in general very elderly.

Atrial fibrillation (AF) is the most common cardiac arrhythmia and an important cause of cardiovascular morbidity and mortality worldwide1. It is already known that the prevalence and incidence of AF increase with aging and they are higher in men than in women, and the prevalence of AF is lower in Chinese than in Caucasian2. Approximately 8 million Chinese adults suffer from AF2. Moreover, AF accounts for a 4 to 5-fold increased risk of stroke and is responsible for approximately 15% of all strokes in the United States3.

As the end product of purine metabolism in humans, serum uric acid (SUA) is an independent marker of morbidity and mortality in a variety of cardiovascular diseases4,5. It has been reported that hyperuricemia is associated with many cardiovascular diseases, including heart failure, hypertension, ischemic heart disease, and stroke5–8. Although previous studies have reported that hyperuricemia is positively associated with AF in patients with different diseases, less is known in the community general population, especially in the very elderly9–11. Especially, very elderly were not pre specified as study subjects. Therefore, this study aimed to describe the rest ECG based AF prevalence in community very elderly Chinese in Chengdu and investigate the association between SUA and AF.

Results
Characteristics of Study Population. Of the 1056 very elderly participants, 18 participants were excluded because of incomplete data. Therefore, 1038 participants with a mean age of 83.6 ± 3.4 years were enrolled in final analysis, 49.8% of which were men. Participants with AF (n = 55) were older and had significantly higher SUA level, diastolic BP and heart rate than those without AF (all Ps <0.05). However, participants with AF had significantly lower levels of TC, TG, LDL-C and pulse pressure (PP) (all Ps <0.05) (Table 1).

SUA level and prevalence of Hyperuricemia. The mean level of SUA in overall participants was 350.1 ± 84.5 μmol/L. Participants with AF had a significantly higher SUA level (382.3 ± 94.0 μmol/L vs 348.9 ± 89.6 μmol/L, p = 0.005). The estimated prevalence of hyperuricemia was 33.0% (n = 342) and there was no sex difference (30.2% for men and 35.6% for women, p = 0.075).
Table 1. Characteristics of Participants. Data are presented as mean ± standard deviation or Percentage(number). P value from comparison between AF group and non AF group. ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blockers; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate, FBG, fasting blood glucose; LDL-C, Low-density lipoprotein cholesterol; MI, myocardial infarction; PP, pulse pressure; SBP, systolic blood pressure; SUA, serum uric acid; TC, total cholesterol; TG, triglycerides. eGFR was calculated according to Cockcroft-Gault equation.

|                          | Total n = 1038 | AF n = 55  | Non AF n = 983 | p value |
|--------------------------|---------------|-----------|---------------|---------|
| Age (years)              | 83.6 ± 3.4    | 83.9 ± 3.6| 83.6 ± 3.4    | 0.552   |
| Current smoker, %(n)     | 11.1 (115)    | 5.5 (5)   | 11.4 (112)    | 0.173   |
| Current drinker, %(n)    | 8.3 (86)      | 14.5 (8)  | 8.0 (78)      | 0.125   |
| Medical history, %(n)    |               |           |               |         |
| Hypertension             | 52.6 (546)    | 56.4 (31) | 52.4 (515)    | 0.566   |
| DM                       | 12.3 (128)    | 9.1 (5)   | 12.5 (123)    | 0.453   |
| Stroke                   | 8.8 (91)      | 5.5 (3)   | 9.0 (88)      | 0.470   |
| MI                       | 7.2 (75)      | 7.3 (4)   | 7.2 (71)      | 0.989   |
| Medication %(n)          |               |           |               |         |
| ACEI/ARB                 | 11.9 (124)    | 12.7 (7)  | 11.9 (117)    | 0.854   |
| CCB                      | 26.1 (271)    | 34.5 (19) | 25.6 (252)    | 0.143   |
| β-receptor blocker       | 7.8 (81)      | 20.0 (11) | 7.1 (70)      | 0.002   |
| Diuretics                | 6.6 (68)      | 3.6 (2)   | 6.7 (66)      | 0.574   |
| BMI (kg/m²)              | 23.1 ± 3.7    | 23.7 ± 4.1| 23.1 ± 3.7    | 0.282   |
| SBP (mmHg)               | 146.4 ± 20.6  | 145.4 ± 21.0| 146.6 ± 22.4 | 0.830   |
| DBP (mmHg)               | 74.1 ± 11.9   | 82.5 ± 14.9| 73.7 ± 11.7   | <0.001  |
| PP (mmHg)                | 72.5 ± 17.1   | 63.9 ± 16.1| 73.6 ± 18.2   | <0.001  |
| Heart rate (bpm)         | 70.0 ± 9.0    | 72.0 ± 14.9| 69.5 ± 7.6    | 0.005   |
| FBG (mmol/L)             | 5.53 ± 1.35   | 5.37 ± 1.19| 5.55 ± 1.38   | 0.081   |
| TC (mmol/L)              | 4.87 ± 0.99   | 4.46 ± 0.97| 4.89 ± 0.98   | 0.001   |
| TG (mmol/L)              | 1.34 ± 0.57   | 1.15 ± 0.51| 1.37 ± 0.80   | 0.020   |
| LDL-C (mmol/L)           | 2.58 ± 0.74   | 2.27 ± 0.70| 2.60 ± 0.74   | 0.001   |
| SUA (µmol/L)             | 350.1 ± 84.5  | 382.3 ± 94.0| 348.9 ± 89.6 | 0.005   |
| Creatinine, µmol/L       | 104.1 ± 32.4  | 110.2 ± 27.8| 103.9 ± 33.0 | 0.008   |
| e GFR, ml/(min 1.73 m²)  | 58.7 ± 13.9   | 55.3 ± 13.5| 58.6 ± 13.9   | 0.084   |

Estimated Prevalence of AF. The variability of ECG analysis was about 3.0% (31/1038). The overall estimated prevalence of AF was 5.3% in our study population. And there was no sex difference in prevalence of AF (5.8% for men and 4.8% for women, p = 0.401). The overall AF prevalence was the highest in participants aged from 85 to 89 year. Men aged older than 90 years had the highest prevalence, while women aged 85 to 89 year had the highest prevalence of AF (Table 2).

Overall AF prevalence in participants with hyperuricemia, or with obesity, or with hypertension and with DM was 10.3%, 7.6%, 5.9% and 5.7%, respectively. In addition, AF prevalence in participants with newly diagnosed hypertension or DM was relatively higher, compared with which in self reported hypertensive participants or diabetic participants (p = 0.949 for comparison between newly diagnosed and self reported hypertension, p = 0.245, for comparison between newly diagnosed and self reported DM). As well, AF prevalence in participants with hyperuricemia (p = 0.020, compared with non hyperuricemia participants) or obesity (p < 0.001, compared with non obesity) was significantly higher (Table 2).

Hyperuricemia and AF. In multiple logistic regression model, after adjustment for age, sex, smoking, obesity, hypertension, DM, PP, TG, TC, and e GFR, hyperuricemia was an independent factor for AF in overall participants (odds ratio (OR): 2.080, 95%CI: 1.103–4.202, P = 0.007, Table 3), in participants with hypertension (OR: 2.452, 95%CI: 1.230–5.238, P = 0.002) or patients with DM (OR: 10.254, 95%CI: 1.350–67.137, P = 0.020) after adjustment for factors above, hyperuricemia was also a factor for AF (Table 3). When SUA was included as continuous variable, it is also an independent factor for AF in overall participants (OR: 1.521, 95%CI: 1.256–5.754, P = 0.003) in participants with hypertension (OR: 1.736, 95%CI: 1.131–6.574, P = 0.030) or patients with DM (OR: 1.106, 95%CI: 1.099–1.0935, P = 0.049).

The optimal cutoff point for SUA predicting AF was 370.5 µmol/L in overall very elderly (p = 0.006), 370.5 µmol/L in very elderly with hypertension (p = 0.012) and 397.0 µmol/L in very elderly with DM (p = 0.077) according to the ROC curve. The sensitivity and specificity of SUA ≥370.5 µmol/L for predicting AF were 62.7% and 61.5% in overall very elderly, respectively.
The main findings in this community-based study are as follows: First, we found that the prevalence of AF in the community very elderly was relatively high. Second, hyperuricemia was associated with the prevalence of AF in general very elderly Chinese in Chengdu.

**AF prevalence.** To our knowledge, in China, until now, there is not a large national-wide epidemiological survey focusing on AF prevalence. Moreover, recent epidemiological studies on AF were more about either local epidemiological status of AF in population younger than 80 years old or in patients with special characteristics. A recent study using in-hospital record data in Yunnan reported that AF prevalence in patients 80 years older was about 0.77%, which may only represent the prevalence in population received medical treatment. Another study in Shanghai with more than 350 patients older than 80 years in a newly urbanized suburban town reported a similar AF prevalence with our study, which was about 5.9%. Moreover, a survey including about 1000 elderly older than 75 years in eight Chinese longevity areas, reported that the AF prevalence in subjects older than 80 years was 8.8%, which was a little higher than the prevalence in our study. The prevalence of AF in our study population was relatively lower than prevalences above in other studies. One possible reason is that our study subjects were the very elderly in community while not in hospital patients or subjects with specific diseases, therefore, this study should be more accurately representative of the real epidemiological situation in the general very elderly.

**Association between UA and AF.** In this study, participants with AF had a higher SUA level compared with participants without AF. Moreover, the prevalence of AF in participants with hyperuricemia was significant higher than in those without hyperuricemia. And our study also demonstrated that hyperuricemia was a factor for AF not only in general very elderly but also in very elderly with hypertension and DM, which is in accordance with another study in patients with DM.

High SUA level has been found to be associated with AF in patients with chronic systolic heart failure. High SUA level was also associated with prevalent AF in hypertensive patients without significant comorbidities, and the development of AF in elderly people with normal blood pressure. Also, SUA level was significantly associated with AF in general Japanese population. Our study further confirmed this association between hyperuricemia and AF, and added information about this association in very elderly population. Although the mechanism of association between hyperuricemia and AF is not well understood, studies have suggested that oxidative stress and inflammation are the most likely contributing factors for AF development. The increase of superoxide and its reactive metabolites through activation of xanthine oxidase may contribute to the pathological consequences of AF such as thrombosis, inflammation, and tissue remodeling. Hyperuricemia could induce protein expression in cells, causing inflammation through activation of uric acid transporters and increased angiotensin II receptors and increased angiotensin II levels, which were ameliorated by ACE inhibitors, UA.

### Table 2. Prevalence of AF. Percentages represent the number with atrial fibrillation/total population. P value are from comparison between men and women. AF indicates atrial fibrillation; DM, diabetes mellitus; IFG, impaired fasting glucose; NFG, normal fasting glucose.

|                    | Prevalence of AF, % (n) |
|--------------------|-------------------------|
|                    | Total | Men | Women | p value |
| **Total**          | 5.3 (55) | 5.8 (30) | 4.8 (25) | 0.401 |
| **Age 80–84**      | 4.7 (34) | 5.8 (21) | 3.6 (13) | 0.146 |
| **85–89**          | 6.9 (17) | 5.6 (7) | 8.2 (10) | 0.552 |
| **≥90**            | 5.8 (4) | 6.3 (2) | 5.4 (2) | 0.976 |
| **Participants with** | | | | |
| Hypertension       | 5.9 (47) | 7.2 (28) | 4.7 (19) | 0.137 |
| New hypertension   | 6.0 (15) | 7.7 (10) | 4.1 (5) | 0.234 |
| Self reported hypertension | 5.9 (32) | 6.9 (18) | 4.9 (14) | 0.324 |
| Prehypertension    | 2.9 (5) | 2.4 (2) | 3.3 (3) | 0.717 |
| Normotension       | 4.4 (3) | 4.7 (2) | 4.0 (1) | 0.900 |
| DM                 | 5.7 (12) | 6.3 (7) | 5.1 (5) | 0.709 |
| New DM             | 8.6 (5) | 10.8 (4) | 5.6 (1) | 0.658 |
| Self reported DM   | 4.6 (7) | 4.1 (3) | 5.0 (4) | 0.778 |
| IFG                | 3.0 (2) | 5.1 (2) | 0 | 0.509 |
| NFG                | 5.4 (41) | 6.3 (23) | 4.5 (18) | 0.292 |
| Obesity            | 10.3 (10) | 14.6 (6) | 7.1 (4) | 0.314 |
| Non-obesity        | 4.8 (45) | 5.5 (26) | 4.1 (19) | 0.323 |
| Hyperuricemia      | 7.6 (26) | 10.3 (16) | 5.4 (10) | 0.108 |
| Non-hyperuricemia  | 4.2 (29) | 4.4 (16) | 3.9 (13) | 0.716 |
transporter blockers, and antioxidants. Therefore, accumulation of UA inside atrial cardiomyocytes might cause atrial structural remodeling, which provides a vulnerable substrate for AF triggering mostly by either oxidative stress, inflammation, or both.

Study limitations. There are several limitations in this study. First, this cross-sectional study could only reflect the associations between factors and AF. Second, AF is often asymptomatic and can be intermittent, therefore widely used rest ECG could not detect all paroxysmal AF. However, AF prevalence is similar to results of studies in other Chinese cities using the same AF detection method. Third, our study could only describe epidemiological distribution in very elderly in Chengdu, therefore our findings may limit generalizability to other very elderly population in China or other regions.

The prevalence of AF is relatively frequent in this community very elderly. No significant sex difference was found in this study. Hyperuricemia is associated with the prevalence of AF in general community very elderly Chinese in Chengdu.

Methods
Study population. This study was designed as a cross-sectional study in general community very elderly (≥80 years old) in Chengdu. From May 2013 to May 2015, a representative sample of very elderly men and women in Chengdu were recruited by using of a stratified three-stage cluster sampling design. A total of 1056 very elderly from 20 residential communities were sampled according to registration data from Chengdu government.

|                | Total       | Hypertension | DM          |
|----------------|-------------|--------------|-------------|
| Age (years)    |             |              |             |
| 80–84          | Ref.        | Ref.         | Ref.        |
| 85–89          | 1.971 (0.995–3.860) | 2.842 (1.363–6.575)* | 3.062 (0.484–20.013) |
| ≥90            | 2.026 (0.646–6.248) | 4.153 (1.148–13.462)* | 0.000       |
| Sex            |             |              |             |
| Men            | Ref.        | Ref.         | Ref.        |
| Women          | 0.706 (0.357–1.270) | 0.701 (0.335–1.417) | 0.524 (0.101–3.362) |
| Smoking        |             |              |             |
| No             | Ref.        | Ref.         | Ref.        |
| Yes            | 0.344 (0.102–1.465) | 0.421 (0.11–1.825) | 1.040 (0.072–17.234) |
| Obesity        |             |              |             |
| No             | Ref.        | Ref.         | Ref.        |
| Yes            | 2.502 (1.114–6.041)* | 3.032 (1.115–6.371)* | 3.53 (0.392–30.348) |
| Hypertension   |             |              |             |
| No             | Ref.        | —            | Ref.        |
| Yes            | 3.637 (1.385–9.325)* | 3.317 (0.279–45.436) |
| PP (mmHg)      |             |              |             |
| <60            | Ref.        | Ref.         | Ref.        |
| 60–79          | 0.301 (0.125–0.652)* | 0.232 (0.108–0.552)* | 0.503 (0.084–3.013) |
| ≥80            | 0.115 (0.047–0.314)* | 0.101 (0.041–0.266)* | 0.000       |
| DM             |             |              |             |
| No             | Ref.        | Ref.         | —           |
| Yes            | 0.725 (0.323–1.561) | 0.716 (0.301–1.622) |
| Hyperuricemia  |             |              |             |
| No             | Ref.        | Ref.         | Ref.        |
| Yes            | 2.080 (1.103–4.202)* | 2.452 (1.230–5.238)* | 10.254 (1.350–67.137)* |
| TG > 1.7 mmol/L|             |              |             |
| No             | Ref.        | Ref.         | Ref.        |
| Yes            | 0.339 (0.114–1.068) | 0.416 (0.128–1.405) | 0.231 (0.033–3.262) |
| TC > 5.2 mmol/L|             |              |             |
| No             | Ref.        | Ref.         | Ref.        |
| Yes            | 0.452 (0.200–1.102) | 0.395 (0.160–1.315) | 0.213 (0.025–3.325) |
| eGFR ≤60 ml/min/1.73 m²|     |              |             |
| No             | Ref.        | Ref.         | Ref.        |
| Yes            | 2.576 (1.370–6.038)* | 3.402 (1.415–8.328)* | 2.732 (1.248–16.348)* |

Table 3. Multiple logistic regression analysis of risk factors for AF in total and subgroups. All models included age, sex, smoking, obesity, hypertension, DM, PP, TG, TC, eGFR and hyperuricemia. *P < 0.05 versus reference category. AF indicates atrial fibrillation; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; PP, pulse pressure; TC, total cholesterol; TG, triglycerides.
Inclusion criteria were permanent residents of the households with a record in the household registration (by identity card or permanent residence booklet checking) and living in local communities at least 3 years. Exclusion criteria were participants with any secondary hypertension, severe frailty, neurologic and psychological diseases (such as Alzheimer’s disease or schizophrenia, etc.), and disabilities or other problems who could not fully participate in this survey. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the Ethics Committee of the Second People’s Hospital of Chengdu. All participants gave informed consent.

**Data Collection and measurement.** Data were collected during clinic visits by well trained physicians and nurses using a questionnaire-based face-to-face interview. Data on basic demographic characteristics, medical history, lifestyle risk factors were obtained from a standardized questionnaire during the interview with participating investigators.

Rest 12-lead electrocardiogram (ECG) (ECG-1350P, Nihon Kohden, Japan) for participants was performed by a well trained physician. ECGs were analyzed by two experienced cardiologists independently for the determination of AF, defined according to the 2011 ACC/AHA/ESC guidelines. Atrial flutter, atrial tachycardia, other arrhythmia and abnormalities were also recorded, but only AF was included in the present analysis. The disagreement of analysis results was checked by a third cardiologist.

Fasting blood samples were collected in the morning after at least 8 h of fasting for all participants. SUA and other biochemical parameters, such as fast glucose (FG), total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) were analyzed enzymatically on an auto-analyzer (AU5421 Chemistry Analyzer, Beckman, Brea, California, United States) in the central laboratory of the Second People’s Hospital of Chengdu.

Blood pressure (BP) were measured three times at two-minute intervals after at least 5 min of rest using a standardized automatic electronic sphygmomanometer (HEM-7300, Omron, Kyoto, Japan) according to the Chinese Guidelines for Prevention and Treatment of Patients with Hypertension. Weight and height were also measured. The body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters.

**Definitions.** AF was diagnosed based on rest ECG findings (absence of consistent P waves, presence of rapid, irregular f waves with a frequency of 350–600 beats/min, and an irregular ventricular response).

Hyperuricemia was defined by the levels of SUA >416 µmol/L (7.0 mg/dL) for men and >357 µmol/L (6.0 mg/dL) for women or if they were on allopurinol therapy.

Hypertension was defined as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg and/or self-reported treatment of hypertension with antihypertensive medication (including diuretics) in the last 2 weeks according to the Chinese Guidelines on Prevention and Control of Hypertension. Impaired fasting glucose (IFG) was diagnosed if 6.1 mmol/L ≤ FG < 7.0 mmol/L. Diabetes mellitus (DM) was diagnosed if FG ≥7.0 mmol/L, or FG <7.0 mmol/L with a past history of DM. Obesity was defined as body max index (BMI) at least 28.0 kg/m² according to World Health Organization guidelines for the Asian Pacific population.

**Statistical analysis.** Analyses were performed using SPSS software (Version 17.0, SPSS Inc, Chicago, IL). Continuous variables are expressed as mean ± standard deviation, and their normality was checked by the Shapiro-Wilk test. Frequencies are presented as percentages with 95% confidence interval (95%CI). Statistical comparison of means between groups was conducted using Student’s t-test or Wilcoxon signed-rank test. And x2 test was applied to compare proportions. Stepwise multiple logistic regression models were used to evaluate the association between risk factors and AF. The receiver operating characteristic (ROC) curve analysis was used to evaluate the efficiency of SUA in predicting AF. A two-sided P value < 0.05 was considered statistically significant.

**References**

1. Kannel, W. B., Abbott, R. D., Savage, D. D. & McNamara, P. M. Coronary heart disease and atrial fibrillation: the Framingham Study. *Am Heart J.* 106, 389–396 (1983).
2. Hu, D. & Sun, Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. *J Am Coll Cardiol.* 52, 865–868 (2008).
3. Wolf, P. A., Abbott, R. D. & Kannel, W. B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke.* 22, 983–988 (1991).
4. Bae, M. H. *et al.* Serum uric acid as an independent and incremental prognostic marker in addition to n-terminal pro-b-type natriuretic peptide in patients with acute myocardial infarction. *Circ J.* 75, 1440–1447 (2011).
5. Tamariz, L. *et al.* Uric acid as a predictor of all-cause mortality in heart failure: A meta-analysis. *Congest Heart Fail.* 17, 25–30 (2011).
6. Wei, F. *et al.* Associations between serum uric acid and the incidence of hypertension a Chinese senior dynamic cohort study. *J Transl Med.* 14, 110 (2016).
7. Li, M. *et al.* Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. *Sci Rep.* 6, 19520 (2016).
8. Mazza, A. *et al.* Predictors of stroke mortality in elderly people from the general population: The Cardiovascular Study in the Elderly. *Eur J Epidemiol.* 17, 1097–1104 (2001).
9. Valbusa, F. *et al.* Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus. *Am J Cardiol.* 112, 499–504 (2013).
10. Liu, T., Zhang, X., Korantzopoulos, P., Wang, S. & Li, G. Uric acid levels and atrial fibrillation in hypertensive patients. *Intern Med.* 50, 799–803 (2011).
11. Zhao, Q. Y. *et al.* Serum uric acid levels correlate with atrial fibrillation in patients with chronic systolic heart failure. *Chin Med J (Engl).* 125, 1708–1712 (2012).
12. Sun, G. Z. *et al.* Prevalence of atrial fibrillation and its risk factors in rural China a cross-sectional study. *Int J Cardiol.* 182, 13–17 (2015).
13. Carrera, P., Thongprayoon, C., Cheungpasitporn, W., Iyer, V. N. & Moua, T. Epidemiology and outcome of new-onset atrial fibrillation in the medical intensive care unit. *J Crit Care.* 36, 102–106 (2016).
14. Guo, Y. et al. Prevalence, incidence, and lifetime risk of atrial fibrillation in China. Chest. 147, 109–119 (2015).
15. Li, L. H. et al. The prevalence, incidence, management and risks of atrial fibrillation in an elderly Chinese population. BMC Cardiovasc Disord. 15, 31 (2015).
16. Chet, C. L. et al. Prevalence and Risk Factors of Atrial Fibrillation in Chinese Elderly: Results from the Chinese Longitudinal Healthy Longevity Survey. Chin Med J (Engl). 128, 2426–2432 (2015).
17. Mantovani, A. et al. Hyperuricemia is Associated With an Increased Prevalence of Paroxysmal Atrial Fibrillation in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. J Endocrinol Invest. 41, 223–231 (2018).
18. Tekin, G., Tekin, Y. K., Erbay, A. R., Turhan, H. & Yetkin, E. Serum uric acid levels are associated with atrial fibrillation in patients with ischemic heart failure. Angiology. 64, 300–303 (2013).
19. Chuang, S. Y. et al. Hyperuricemia and incident atrial fibrillation in a normotensive elderly population in Taiwan. Nutr Metab Cardiovasc Dis. 24, 1020–1026 (2014).
20. Kawaseo, S. et al. Uric Acid Level and Prevalence of Atrial Fibrillation in a Japanese General Population of 285,882. Circ J. 80, 2453–2459 (2016).
21. Dudley, S. C. Jr. et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases. Circulation. 112, 1266–1273 (2005).
22. Sakabe, M. et al. Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Electrophysiol. 23, 1130–1135 (2012).
23. Kanellis, J. et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 41, 1287–1293 (2003).
24. Zhang, Y. et al. Uric acid induces oxidative stress and growth inhibition by activating adenine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells. Mol Cell Endocrinol. 375, 89–96 (2013).
25. Yu, M. A., Sánchez-Lorada, L. G., Johnson, R. J. & Kang, D. H. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. J Hypertens. 28, 1234–1242 (2010).
26. Corry, D. B. et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens. 26, 269–275 (2008).
27. Huang, G. et al. Hyperuricemia is associated with cardiovascular diseases clustering among very elderly women-a community based study in Chengdu, China. Scientific Reports. 7, 996 (2017).
28. Fuster, V. et al. ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011, e269–367 (2011).
29. Liu, L. S. Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi. 39, 579–615 (2011).
30. Chinese Diabetes Society. China Guideline for Type 2 Diabetes. Beijing: Beijing University Medical Publication House; 2011.
31. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363, 157–163 (2004).

Acknowledgements
We are grateful to the study participants for their participation in the study. We also appreciate Ms. Hui-xing Yang for her work for this study. This study was supported by the Science and Technology Bureau of Chengdu, Sichuan, China (contract: 11PPYB034SF).

Author Contributions
T.J.Z. and G.H. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. T.J.Z., G.H. and J.B.X. contributed to study concept and design, data analysis and interpretation, and drafting of manuscript. R.H.X., Z.H.L., X.X. and Y.L. contributed to study conduct and data acquisition.

Additional Information
Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2018